SUPERNUS PHARMACEUTICA

Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults

29 Apr 2022 20:00:38 By Nasdaq GlobeNewswire

Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results

13 Apr 2022 16:11:14 By Nasdaq GlobeNewswire

Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance

04 Apr 2022 17:00:00 By Nasdaq GlobeNewswire

Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance

17 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Supernus to Participate in Annual Cowen Health Care Conference

02 Mar 2022 08:00:01 By Nasdaq GlobeNewswire

Supernus Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results

28 Feb 2022 16:05:01 By Nasdaq GlobeNewswire

Supernus to Provide Preliminary Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022

22 Feb 2022 16:30:00 By Nasdaq GlobeNewswire

Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA

22 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device

08 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Targeted in Ransomware Incident

24 Nov 2021 18:58:37 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Completes Acquisition of Adamas Pharmaceuticals

24 Nov 2021 09:12:51 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Adamas Pharmaceuticals Tender Offer

23 Nov 2021 08:00:00 By Nasdaq GlobeNewswire

Supernus to Participate in Annual Piper Sandler Healthcare Conference

18 Nov 2021 08:00:02 By Nasdaq GlobeNewswire

Supernus to Participate in Upcoming November Investor Conferences

10 Nov 2021 16:05:03 By Nasdaq GlobeNewswire

Supernus Announces Third Quarter 2021 Financial Results

03 Nov 2021 16:01:01 By Nasdaq GlobeNewswire

Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021

27 Oct 2021 17:42:55 By Nasdaq GlobeNewswire

Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month

20 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio

11 Oct 2021 06:30:00 By Nasdaq GlobeNewswire

Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

02 Sep 2021 18:45:00 By Nasdaq GlobeNewswire

Supernus to Participate in Upcoming September Investor Conferences

02 Sep 2021 09:00:00 By Nasdaq GlobeNewswire